AstraZeneca plc (ADR)  

(Public, NYSE:AZN)   Watch this stock  
Find more results for AZN
76.01
+1.77 (2.38%)
Aug 29 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 75.36 - 76.24
52 week 48.53 - 82.68
Open 75.57
Vol / Avg. 2.76M/2.82M
Mkt cap 94.02B
P/E 46.58
Div/yield 0.90/3.68
EPS 1.63
Shares 1.26B
Beta 0.51
Inst. own 8%
Nov 6, 2014
Q3 2014 AstraZeneca PLC Earnings Release Add to calendar
Jul 31, 2014
Q2 2014 AstraZeneca PLC Earnings Call - Webcast
Jul 31, 2014
Q2 2014 AstraZeneca PLC Earnings Release
Jun 19, 2014
AstraZeneca PLC at Citi European Healthcare Conference
Jun 3, 2014
AstraZeneca PLC at Jefferies Global Healthcare Conference
Jun 2, 2014
AstraZeneca PLC ASCO Analyst Briefing
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 7.89% 10.00%
Operating margin 13.03% 14.44%
EBITD margin - 44.27%
Return on average assets 3.52% 4.70%
Return on average equity 9.05% 10.89%
Employees 51,500 -
CDP Score - 85 B

Address

2 Kingdom Street, Paddington
LONDON, ENG W2 6BD
United Kingdom - Map
+44-20-76048000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In January 2014, Probiodrug AG transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. In February 2014, Bristol-Myers Squibb Co completed the sale of its global diabetes business to AstraZeneca.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 55
Bio & Compensation  - Reuters
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 61
Bio & Compensation  - Reuters
Ruud Dobber Executive Vice President, Europe
Bio & Compensation  - Reuters
Caroline Hempstead Interim Executive Vice-President, Human Resources & Corporate Affairs
Bio & Compensation  - Reuters
Paul Hudson Executive Vice President, North America
Bio & Compensation  - Reuters
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Bio & Compensation  - Reuters
Mark Mallon Executive Vice President, International
Bio & Compensation  - Reuters
Briggs Morrison Executive Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Menelas Pangalos Executive Vice President - Innovative Medicines
Bio & Compensation  - Reuters
David Smith Executive Vice President - Operations and Information Services
Bio & Compensation  - Reuters